DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: Analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors

Histopathology

Volumn 60, Issue 3, 2012, Pages 489-496

  Lima, Lucianne Maia Costa ^a,b   De Souza, Ludmilla Regina ^b   Da Silva, Thiago Fonseca ^b   Pereira, Camila Santos ^b   Guimarães, André Luiz Sena ^b   De Paula, Alfredo Maurício Batista ^b   De Andrade Carvalho, Heloisa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b STATE UNIVERSITY OF MONTES CLAROS   (Brazil)

Author keywords

Adjuvant; DNA repair; Genetic polymorphism; Head and neck neoplasms; Immunohistochemistry; Methylation; Radiotherapy; Squamous cell carcinoma

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADULT; AGED; ALLELE; ARTICLE; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CONTROLLED STUDY; DNA METHYLATION; DNA POLYMORPHISM; DNA REPAIR; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENE FREQUENCY; GENE SILENCING; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; METHYLATION; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84856275667     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04062.x     Document Type: Article

References (25)

1. Koskinen WJ, Partanen J, Vaheri A, Aaltonen LM. HLA-DRB1, -DQB1 alleles in head and neck carcinoma patients. Tissue Antigens 2006; 67; 237-240.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371; 1695-1709.
3. Toruner GA, Ulger C, Alkan M et al. Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genet. Cytogenet. 2004; 154; 27-35.
4. Mizuno S, Chijiwa T, Okamura T et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97; 1172-1179.
5. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003; 349; 2042-2054.
6. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006; 355; 983-991.
7. Handra-Luca A, Hernandez J, Mountzios G et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin. Cancer Res. 2007; 13; 3855-3859.
8. Carles J, Monzo M, Amat M et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2006; 66; 1022-1030.
9. Wang SL, Zhao H, Zhou B et al. Polymorphisms in ERCC1 and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Leuk. Res. 2006; 30; 1341-1345.
10. Chen HY, Shao CJ, Chen FR, Kwan AL, Chen ZP. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int. J. Cancer 2010; 126; 1944-1954.
11. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 1996; 93; 9821-9826.
12. Jun HJ, Ahn MJ, Kim HS et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br. J. Cancer 2008; 99; 167-172.
13. Hoeijmakers JH. From xeroderma pigmentosum to the biological clock contributions of Dirk Bootsma to human genetics. Mutat. Res. 2001; 485; 43-59.
14. Winsey SL, Haldar NA, Marsh HP et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res. 2000; 60; 5612-5616.
15. Nexo BA, Vogel U, Olsen A et al. A specific haplotype of single nucleotide polymorphisms on chromosome 19q13.2-3 encompassing the gene RAI is indicative of post-menopausal breast cancer before age 55. Carcinogenesis 2003; 24; 899-904.
16. Tomescu D, Kavanagh G, Ha T, Campbell H, Melton DW. Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma. Carcinogenesis 2001; 22; 403-408.
17. Vogel U, Nexo BA, Wallin H, Overvad K, Tjonneland A, Raaschou-Nielsen O. No association between base excision repair gene polymorphisms and risk of lung cancer. Biochem. Genet. 2004; 42; 453-460.
18. Yin J, Hedayati MA, Grossman L, Bolund L, Nexo BA. Rapid genotyping of human ERCC1 exon 4 polymorphism with fluorescence analysis using fluorophore-labeled hybridization probes and a lightcycler. Biochem. Genet. 2002; 40; 143-148.
19. Yin J, Vogel U, Gerdes LU, Dybdahl M, Bolund L, Nexo BA. Twelve single nucleotide polymorphisms on chromosome 19q13.2-13.3: linkage disequilibria and associations with basal cell carcinoma in Danish psoriatic patients. Biochem. Genet. 2003; 41; 27-37.
20. Mort R, Mo L, McEwan C, Melton DW. Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br. J. Cancer 2003; 89; 333-337.
21. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol. Biomarkers Prev. 2002; 11; 1513-1530.
22. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 2002; 128; 1084-1088.
23. Feinberg AP. The epigenetics of cancer etiology. Semin. Cancer Biol. 2004; 14; 427-432.
24. Momparler RL. Cancer epigenetics. Oncogene 2003; 22; 6479-6483.
25. Gossage L, Madhusudan S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat. Rev. 2007; 33; 565-577.